Gaithersburg biotechnology company GenVec reported a net loss of $14.1 million for 2012, compared with a net loss of $7.4 million for 2011. Revenue decreased 47 percent, to $9.4 million, in 2012 from 2011, primarily due to decreased revenue generated from hearing loss and balance disorders, HIV, and foot and mouth disease programs.
For the fourth quarter, the company showed a net loss of $3.2 million, compared with a net loss of $2.5 million for the comparable prior year period. Revenues declined to $1.5 million, from $3.4 million.
Rockville biotechnology company EntreMed reported a net loss of $4.5 million for 2012, about the same as in 2011. Revenues declined to about $670,000, from $1.9 million.
The net loss in the fourth quarter of about $400,000 was down from net income of $1.0 million in 2011’s fourth quarter.
Bethesda enriched uranium fuel supplier USEC reported a net loss for 2012 of $1.2 billion, greater than the $491 million loss in 2011. The loss was largely due to $1.1 billion in expenses associated with the American Centrifuge project. Revenues rose by 15 percent, to $1.9 billion.
USEC showed a net loss of $1.1 billion in the fourth quarter, more than the $446 million loss a year earlier. Revenues declined by 9 percent, to $421.3 million.
Chindex International of Bethesda, which provides health care services in China, saw revenues in 2012 increase by 33 percent, to $152.4 million, from 2011. Net income jumped by 28 percent, to $4.1 million.
Fourth-quarter revenues rose 36 percent, to $43.5 million, from a year earlier. Net income about tripled to $3.5 million.
Cytomedix reported that 2012 revenues increased by 47 percent to $10.6 million from 2011. The Gaithersburg biotech showed a loss to common stockholders of $19.8 million, greater than the $3.9 million loss in 2011.
Fourth-quarter revenues declined by 29 percent, to $2.1 million, while the net loss widened to $3.8 million, from $800,000 a year earlier.
Rockville biotech Neuralstem narrowed its loss for 2012 to $10.1 million, down from $12.5 million in 2011. The business had lower expenses for stock-based compensation, operational costs on studies and legal fees. Revenues, which were $391,000 in 2011, declined to $234,000.
In February, the company raised about $5.2 million through an offering of its common stock to fund ongoing clinical trials and other purposes.